Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capecitabine - Roche

Drug Profile

Capecitabine - Roche

Alternative Names: Capecitabine RDT; R340; RG 340; RO 091978; Ro09-1978; Xeloda

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Alliance for Clinical Trials in Oncology; Beth Israel Deaconess Medical Center; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Ludwig-Maximilians-University; Roche; Samsung Medical Center; Sanofi; University of Chicago
  • Class Antineoplastics; Carbamates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Colorectal cancer; Gastric cancer
  • Registered Pancreatic cancer; Rectal cancer
  • Phase II Glioma; Intestinal cancer; Oesophageal cancer
  • No development reported Cervical cancer
  • Discontinued Biliary cancer; Lung cancer; Nasopharyngeal cancer

Most Recent Events

  • 28 Jun 2023 Efficacy data from a phase III trial in Colorectal Cancer presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
  • 27 Apr 2023 Chugai Pharmaceuticals submits company opinion for capecitabine for Neuroendocrine tumors to MHLW review comittee (Chugai Pharmaceuticals pipeline, May 2023)
  • 24 Jan 2023 CHEPLAPHARM acquires capecitabin (Xeloda®) from Roche
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top